Literature DB >> 20179086

CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Selim Kuçi1, Zyrafete Kuçi, Hermann Kreyenberg, Erika Deak, Kathrin Pütsch, Sabine Huenecke, Chandrasekhar Amara, Stefanie Koller, Eva Rettinger, Manuel Grez, Ulrike Koehl, Hatixhe Latifi-Pupovci, Reinhard Henschler, Torsten Tonn, Dorothee von Laer, Thomas Klingebiel, Peter Bader.   

Abstract

UNLABELLED: Background In vitro proliferative and differentiation potential of mesenchymal stromal cells generated from CD271(+) bone marrow mononuclear cells (CD271-mesenchymal stromal cells) has been demonstrated in several earlier and recent reports. In the present study we focused, in addition to proliferative and differentiation potential, on in vitro and in vivo immunosuppressive and lymphohematopoietic engraftment-promoting potential of these mesenchymal stromal cells compared to bone marrow-derived mesenchymal stromal cells generated by plastic adherence (plastic adherence-mesenchymal stromal cells). DESIGN AND METHODS: We set up a series of experimental protocols in order to determine the phenotype of CD271-mesenchymal stromal cells, and their clonogenic, proliferative, differentiation and immunosuppressive potential. The potential of CD271-mesenchymal stromal cells to improve the engraftment of CD133(+) hematopoietic stem cells at co-transplantation was evaluated in immunodeficient NOD/SCID-IL2Rgamma(null) mice.
RESULTS: In vitro studies demonstrated that CD271-mesenchymal stromal cells differentiate along adipogenic, osteogenic and chondrogenic lineages (trilineage potential), produce significantly higher levels of cytokines than plastic adherence-mesenchymal stromal cells, and significantly inhibit the proliferation of allogeneic T-lymphocytes in mixed lymphocyte reaction assays. Elevated levels of prostaglandin E(2), but not nitric monoxide, mediated the majority of this immunosuppressive effect. In vivo studies showed that CD271-mesenchymal stromal cells promoted significantly greater lymphoid engraftment than did plastic adherence-mesenchymal stromal cells when co-transplanted with CD133(+) hematopoietic stem cells at a ratio of 8:1 in immunodeficient NOD/SCID-IL2Rgamma(null) mice. They induced a 10.4-fold increase in the number of T cells, a 2.5-fold increase in the number of NK cells, and a 3.6-fold increase in the number of B cells, indicating a major qualitative difference between these two mesenchymal stromal cell populations. Conclusions Our results indicate that CD271 antigen provides a versatile marker for prospective isolation and expansion of multipotent mesenchymal stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. The co-transplantation of such cells together with hematopoietic stem cells in patients with hematologic malignancies may prove valuable in the prevention of impaired/delayed T-cell recovery and graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179086      PMCID: PMC2857196          DOI: 10.3324/haematol.2009.015065

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  48 in total

1.  Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice.

Authors:  Maria Angelopoulou; Enrico Novelli; Joanna E Grove; Henry M Rinder; Curt Civin; Linzhao Cheng; Diane S Krause
Journal:  Exp Hematol       Date:  2003-05       Impact factor: 3.084

2.  Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

Authors:  K Le Blanc; L Tammik; B Sundberg; S E Haynesworth; O Ringdén
Journal:  Scand J Immunol       Date:  2003-01       Impact factor: 3.487

3.  Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation.

Authors:  Pieternella S In 't Anker; Sicco A Scherjon; Carin Kleijburg-van der Keur; Willy A Noort; Frans H J Claas; Roelof Willemze; Willem E Fibbe; Humphrey H H Kanhai
Journal:  Blood       Date:  2003-08-15       Impact factor: 22.113

4.  Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential.

Authors:  Pieternella S in 't Anker; Willy A Noort; Sicco A Scherjon; Carin Kleijburg-van der Keur; Alwine B Kruisselbrink; Rutger L van Bezooijen; Willem Beekhuizen; Roelof Willemze; Humphrey H H Kanhai; Willem E Fibbe
Journal:  Haematologica       Date:  2003-08       Impact factor: 9.941

5.  Human adipose tissue is a source of multipotent stem cells.

Authors:  Patricia A Zuk; Min Zhu; Peter Ashjian; Daniel A De Ugarte; Jerry I Huang; Hiroshi Mizuno; Zeni C Alfonso; John K Fraser; Prosper Benhaim; Marc H Hedrick
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

6.  Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med,low phenotype.

Authors:  Frederic Deschaseaux; Florelle Gindraux; Rafika Saadi; Laurent Obert; David Chalmers; Patrick Herve
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

7.  Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses.

Authors:  Helen Karlsson; Sujith Samarasinghe; Lynne M Ball; Berit Sundberg; Arjan C Lankester; Francesco Dazzi; Mehmet Uzunel; Kanchan Rao; Paul Veys; Katarina Le Blanc; Olle Ringdén; Persis J Amrolia
Journal:  Blood       Date:  2008-04-28       Impact factor: 22.113

8.  Identification of a novel class of human adherent CD34- stem cells that give rise to SCID-repopulating cells.

Authors:  Selim Kuçi; Johannes T Wessels; Hans-Jörg Bühring; Karin Schilbach; Michael Schumm; Gabriele Seitz; Jürgen Löffler; Peter Bader; Paul G Schlegel; Dietrich Niethammer; Rupert Handgretinger
Journal:  Blood       Date:  2002-09-19       Impact factor: 22.113

9.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

Authors:  Mauro Krampera; Sarah Glennie; Julian Dyson; Diane Scott; Ruthline Laylor; Elizabeth Simpson; Francesco Dazzi
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

10.  Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.

Authors:  Israel M Barbash; Pierre Chouraqui; Jack Baron; Micha S Feinberg; Sharon Etzion; Ariel Tessone; Liron Miller; Esther Guetta; Dov Zipori; Laurence H Kedes; Robert A Kloner; Jonathan Leor
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

View more
  69 in total

1.  Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells.

Authors:  Tullia Maraldi; Francesca Beretti; Marianna Guida; Manuela Zavatti; Anto De Pol
Journal:  Stem Cells Transl Med       Date:  2015-04-14       Impact factor: 6.940

2.  Priming with ligands secreted by human stromal progenitor cells promotes grafts of cardiac stem/progenitor cells after myocardial infarction.

Authors:  Yoshitaka Iso; Krithika S Rao; Charla N Poole; A K M Tarikuz Zaman; Ingrid Curril; Burton E Sobel; Jan Kajstura; Piero Anversa; Jeffrey L Spees
Journal:  Stem Cells       Date:  2014-03       Impact factor: 6.277

3.  Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.

Authors:  Zyrafete Kuçi; Julia Seiberth; Hatixhe Latifi-Pupovci; Sibylle Wehner; Stefan Stein; Manuel Grez; Halvard Bönig; Ulrike Köhl; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

Review 4.  Developmental definition of MSCs: new insights into pending questions.

Authors:  Shishu Huang; Victor Leung; Songlin Peng; Laiching Li; Feng Juan Lu; Ting Wang; William Lu; Kenneth M C Cheung; Guangqian Zhou
Journal:  Cell Reprogram       Date:  2011-09-15       Impact factor: 1.987

Review 5.  CD271 as a marker to identify mesenchymal stem cells from diverse sources before culture.

Authors:  María Álvarez-Viejo; Yolanda Menéndez-Menéndez; Jesús Otero-Hernández
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

6.  Comparing stemness gene expression between stem cell subpopulations from peripheral blood and adipose tissue.

Authors:  Maria Teresa González-Garza; Delia E Cruz-Vega; Alejandro Cárdenas-Lopez; Rosa Maria de la Rosa; Jorge E Moreno-Cuevas
Journal:  Am J Stem Cells       Date:  2018-06-01

7.  Hematopoietic stem cell and mesenchymal stem cell population size in bone marrow samples depends on patient's age and harvesting technique.

Authors:  Katja Rebolj; Matija Veber; Matej Drobnič; Elvira Maličev
Journal:  Cytotechnology       Date:  2018-09-18       Impact factor: 2.058

8.  Mesenchymal stromal cell characteristics vary depending on their origin.

Authors:  Heike Wegmeyer; Ann-Marie Bröske; Mathias Leddin; Karin Kuentzer; Anna Katharina Nisslbeck; Julia Hupfeld; Kornelius Wiechmann; Jennifer Kuhlen; Christoffer von Schwerin; Carsten Stein; Saskia Knothe; Jürgen Funk; Ralf Huss; Markus Neubauer
Journal:  Stem Cells Dev       Date:  2013-06-22       Impact factor: 3.272

9.  Age-related inflammation triggers skeletal stem/progenitor cell dysfunction.

Authors:  Anne Marie Josephson; Vivian Bradaschia-Correa; Sooyeon Lee; Kevin Leclerc; Karan S Patel; Emma Muinos Lopez; Hannah P Litwa; Shane S Neibart; Manasa Kadiyala; Madeleine Z Wong; Matthew M Mizrahi; Nury L Yim; Austin J Ramme; Kenneth A Egol; Philipp Leucht
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-20       Impact factor: 11.205

Review 10.  Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential.

Authors:  Miaohua Mo; Shan Wang; Ying Zhou; Hong Li; Yaojiong Wu
Journal:  Cell Mol Life Sci       Date:  2016-05-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.